Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5842420 | 0.92 | MAPT (0.54) | MAPTPOLBTSHRLMNAALDH1A1 | |
| SCHEMBL5841856 | 0.91 | MAPT (0.53) | MAPTALDH1A1NPSR1SMN1; SMN2GAA | |
| SCHEMBL5842446 | 0.89 | MAPT (0.53) | MAPTPOLBTSHRLMNAALDH1A1 | |
| SCHEMBL5842252 | 0.88 | MAPT (0.60) | MAPTPOLBTSHRLMNAALDH1A1 | |
| SCHEMBL5842932 | 0.85 | MAPT (0.60) | MAPTPOLBTSHRALDH1A1NPSR1 | |
| SCHEMBL5844337 | 0.84 | MAPT (0.53) | MAPTPOLBTSHRLMNAALDH1A1 | |
| SCHEMBL5842613 | 0.82 | MAPT (0.56) | MAPTPOLBALDH1A1NPSR1SMN1; SMN2 | |
| SCHEMBL5841312 | 0.82 | MAPT (0.52) | MAPTPOLBTSHRALDH1A1NPSR1 | |
| SCHEMBL5841845 | 0.81 | MEN1 (0.53) | MAPTPOLBALDH1A1NPSR1SMN1; SMN2 | |
| SCHEMBL5844102 | 0.79 | MAPT (0.55) | MAPTPOLBALDH1A1NPSR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192292-A1 | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS AG (CH) | 2005-09-01 | — | — | US | claimed |
| US-7067549-B2 | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS AG (CH) | 2006-06-27 | — | — | US | disclosed |
| US-20050192292-A1 | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS AG (CH) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192292-A1 | Pyrrolidone carboxamides | NPY1R, NPY5R, NPY2R | MAPT 4395/4885POLB 4023/4885TSHR 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.